Why Is HALOZYME THERAPEUTIC (HALO) Stock Up Today?

Why HALO stock is up today

HALO stock surged 20.24% to $103.12 in the session, driven by a revised price target from Wells Fargo, which raised its target to $95 from $75. The move reflects renewed investor optimism about the company's strategic direction and performance. Despite a slight opening gap down, the stock quickly reversed course and closed the session near the upper end of its intraday range.

What Happened

Wells Fargo updated its assessment of Halozyme Therapeutics, increasing its price target to $95. This follows similar upgrades from other analysts, including Leerink Partners, which raised its target to $110, and TD Cowen, which set a new target of $105. These analyst actions signal confidence in the company's growth trajectory and therapeutic pipeline. Meanwhile, Citizens maintained its Market Outperform rating and raised its price target to $93. The cumulative effect of these upgrades contributed to the sharp rise in HALO's share price.

Recent insider transactions show several executives and directors selling shares, with the most recent sale reported on July 9. No insider purchases were recorded in the last 90 days. A single congressional trade was disclosed, with Rep. Gilbert Cisneros purchasing a small stake in the company on March 9.

What The Data Shows

The stock opened at $102.22, a -0.9% gap down from the prior close, but quickly reversed to trade at $102.22 for the session's high and low at 7:05 AM ET. The last trade was also at $102.22, with no shares exchanged so far in the session. HALO has a market cap of $10.2B, a P/E ratio of 30.5, and has seen revenue grow by 41.2% in the trailing twelve months. The stock currently trades within its 52-week range of $61.23 to $103.30.

What To Watch

With no earnings date provided, investors should monitor the breadth of analyst coverage and any further price target adjustments. The stock's recent performance and analyst activity suggest continued interest in the company's long-term potential.